Skip to main content
. 2019 Feb 6;39(4):369–377. doi: 10.1007/s40261-019-00756-x

Table 1.

Demographics and baseline clinical characteristics of patients in modified FAS populationa

Characteristics LOX-T LOX-O p value
n = 91 n = 88
Age, years (%) 45.6 (13.9) 46.4 (14.1) 0.700
Female, n (%) 56 (61.5) 52 (59.1) 0.738
Height, cm (%) 164.5 (8.5) 165.2 (8.0) 0.423
Weight, kg (%) 63.4 (11.8) 64.7 (11.4) 0.476
BMI, kg/cm2 (%) 23.3 (3.2) 23.6 (3.0) 0.552
Affected sites, n (%) 0.808
 Neck 14 (15.4) 10 (11.4)
 Shoulders 17 (18.7) 14 (15.9)
 Arms 4 (4.4) 2 (2.3)
 Back and waist 38 (41.8) 45 (51.1)
 Legs 14 (15.4) 15 (17.0)
 Buttocks 1 (1.1) 0 (0.0)
 Other 3 (3.3) 2 (2.3)
Duration of myalgia (d) 0.905
 Mean (SD) 4.6 (11.6) 8.5 (22.2)
 Median (min–max) 1.0 (1–78) 1.0 (1–98)
Allergy history, n (%) 0 0
Comorbidity, n (%) 11 (12.1) 13 (14.8) 0.598
Medical/surgical history, n (%) 15 (16.5) 17 (19.3) 0.621
Clinical symptoms, n (%)
 Pain at rest 0.049
  No symptom 12 (13.2) 16 (18.2)
  Mild 37 (40.7) 45 (51.1)
  Moderate 40 (44.0) 25 (28.4)
  Severe 2 (2.2) 2 (2.3)
Clinical symptom score at baseline, mean (SD)
 Rest pain 1.4 (0.7) 1.1 (0.7) 0.049
 Tenderness 1.7 (0.7) 1.5 (0.8) 0.251
 Motion pain 1.9 (0.5) 1.8 (0.6) 0.798
 Total score 6.4 (1.6) 5.8 (1.7) 0.010

BMI body mass index, FAS full analysis set, SD standard deviation

aModified FAS population excluded subjects who had history of myalgia for > 10 years; two subjects were excluded from LOX-O study group